Filgotinib in the treatment of inflammatory bowel diseases
Authors:
M. Lukáš
Authors‘ workplace:
Klinické a výzkumné centrum pro střevní záněty, Klinické centrum ISCARE a. s. a 1. LF UK v Praze
Published in:
Gastroent Hepatol 2023; 77(2): 145-146
Category:
doi:
https://doi.org/10.48095/ccgh2023145
Sources
1. Lukáš M. Biologická a inovativní terapie. In: Lukáš M et al. Pokroky v diagnostice a léčbě idiopatických střevních zánětů. Praha: Galén 2019: 183–196.
2. D’Amico F, Magro F, Peyrin-Biroulet L et al. Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis. J Crohns Colitis 2022; 16 (5): 835–844. doi: 10.1093/ecco-jcc/jjab206.
3. Feagan B, Danese S, Loftus EV et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3double-blind, randomized controlled study. Lancet 2021; 397 (10292): 2372–2384. doi: 10.1016/S0140-6736 (21) 00666-8.
Labels
Paediatric gastroenterology Gastroenterology and hepatology SurgeryArticle was published in
Gastroenterology and Hepatology
2023 Issue 2
Most read in this issue
- Autoimmune pancreatitis in childhood
- Neurobiology of liver diseases
- Ultra-processed food – a threat to liver health
- International experience with Crohn’s disease exclusion diet (CDED) with partial enteral nutrition (PEN)